This is a preview using fictional data. Start your own assessment →
Acme BioPharma Inc.
Pharmaceutical Manufacturing • 501-2000 employees • 11/20/2026
Based on the assessment, Acme BioPharma Inc. achieved an overall Audit Readiness Score of 53/100, placing it in the high-risk band at a Basic maturity level. The strongest area is Documentation Readiness (61%), while Data Integrity (40%) represents the most immediate risk to inspection outcomes. 1 critical and 8 major findings were identified, with 1 documentation gaps requiring remediation. Executing the recommended CAPAs over the next 30–90 days will materially reduce regulatory exposure and improve inspection posture.
Compliance Radar
Maturity across the four core domains
Risk Heatmap
Severity distribution per category
Critical Findings
Severity-ranked observations
- MajorValidation documents (IQ/OQ/PQ) complete?Documentation Readiness
- MajorCAPA documentation available and traceable?Documentation Readiness
- MajorALCOA+ principles implemented across systems?Data Integrity
- MajorAudit trails enabled and reviewed?Data Integrity
- CriticalBackup & restore procedures tested?Data Integrity
- MajorCAPA effectiveness reviews performed?Quality Systems
- MajorRisk assessments documented (ICH Q9)?Quality Systems
- MajorMock audits performed in last 12 months?Inspection Readiness
Missing / Incomplete Documentation
Documents likely requested in an inspection
- Backup/restore test reports
Gap Analysis
Detailed view by category and weight
| Category | Score | Weight | Status |
|---|---|---|---|
| Documentation Readiness | 61% | 25% | Developing |
| Data Integrity | 40% | 30% | At Risk |
| Quality Systems | 60% | 25% | At Risk |
| Inspection Readiness | 53% | 20% | At Risk |
Recommended CAPAs
Prioritized corrective and preventive actions
Book a 30-min consultation
Walk through your findings with a senior compliance specialist. We'll prioritize CAPAs and help you build an actionable remediation plan.
Or send us a note
We'll respond within one business day.